Phathom anticipates $1B opportunity in GI market as sales restructuring boosts revenue by 25%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 30 2025
0mins
Should l Buy PHAT?
Source: SeekingAlpha
Management Changes and Financial Performance: Phathom Pharmaceuticals reported a 25% growth in Q3 2025 net revenue, reaching $49.5 million, while significantly reducing operating expenses by 43%. CEO Steven Basta introduced new leadership members to strengthen the company's commercial strategy.
Strategic Focus on Gastroenterology: The company is shifting its sales strategy to prioritize gastroenterology prescribers, with a realignment of sales territories and incentives aimed at accelerating growth in 2026.
Updated Financial Guidance: Management narrowed its full-year revenue guidance to $170 million to $175 million and expects to maintain cash operating expenses below $55 million in Q4, indicating confidence in achieving operating profitability by 2026.
Analyst Sentiment and Risks: While analysts expressed optimism about Phathom's growth, they raised concerns regarding prescription trends, cost management sustainability, and the challenges of changing long-standing prescribing habits among physicians.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PHAT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PHAT
Wall Street analysts forecast PHAT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHAT is 25.40 USD with a low forecast of 16.00 USD and a high forecast of 29.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 12.410
Low
16.00
Averages
25.40
High
29.00
Current: 12.410
Low
16.00
Averages
25.40
High
29.00
About PHAT
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s product candidates include VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker, or potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are two of the most common acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Phathom Pharmaceuticals Sees Q4 Sales of $57-58M, Prices $130M Public Offering
- Sales Forecast Increase: Phathom Pharmaceuticals anticipates Q4 2025 sales between $57 million and $58 million, exceeding the consensus estimate of $56.16 million, indicating strong market competitiveness and growing product demand.
- Annual Revenue Guidance Update: The company has raised its full-year 2025 revenue guidance to approximately $174.5 million to $175.5 million from the previous $170 million to $175 million, reflecting an optimistic outlook for future performance.
- Prescription Milestone: Voquezna has surpassed one million prescriptions dispensed in the U.S. since its launch, demonstrating strong market acceptance and clinical demand for the treatment of gastroesophageal reflux disease (GERD).
- Financing Plan: Phathom Pharmaceuticals successfully priced its underwritten public offering of 6.875 million shares at $16 per share, expected to raise approximately $130 million for general corporate purposes, including working capital and R&D expenses, showcasing the company's financial support capability for future growth.
See More
Northrop Grumman Shares Rise 6.84% Following Military Budget Proposal
- Stock Surge: Northrop Grumman's shares rose 6.84% following President Trump's proposal to increase the 2027 military budget from $1 trillion to $1.5 trillion, indicating market optimism about defense spending that could drive future performance growth.
- Market Reaction: Despite a generally poor market performance, Northrop Grumman's stock increased, reflecting investor confidence in the defense sector, particularly amid current geopolitical tensions where defense spending may become a key economic growth driver.
- Industry Trends: With the anticipated increase in defense budgets, Northrop Grumman is likely to secure more government contracts, enhancing its market share and profitability, thereby solidifying its leadership position in the defense industry.
- Investor Focus: The market remains highly attentive to upcoming economic data, especially initial jobless claims and trade deficit figures, which could influence overall market sentiment and investment decisions.
See More
AZZ Inc Reports Q3 Earnings Beat, Shares Rise 2.1%
- Earnings Beat: AZZ Inc reported adjusted earnings of $1.52 per share for Q3, surpassing market expectations of $1.47, indicating sustained profitability that may attract more investor interest.
- Sales Growth: The company achieved sales of $425.746 million, exceeding expectations of $418.164 million, demonstrating strong market demand and further solidifying its position in the industry.
- Stock Price Surge: In pre-market trading, AZZ Inc shares rose 2.1% to $112.09, reflecting a positive market reaction to its earnings report, which could boost investor confidence in subsequent trading days.
- Optimistic Market Outlook: With improved performance, AZZ Inc is poised to continue attracting investment and enhancing its competitive edge, particularly in the context of the current economic recovery.
See More
Phathom Pharmaceuticals Prices 6.875M Share Offering at $16, Raising $130M
- Public Offering Pricing: Phathom Pharmaceuticals has priced its offering of 6.875 million shares of common stock at $16 per share, along with 1.25 million pre-funded warrants, aiming to raise approximately $130 million to strengthen its capital base for future R&D and commercialization efforts.
- Pre-Funded Warrant Details: The pre-funded warrants are priced at $15.999 each, reflecting the common stock price minus a $0.001 exercise price, showcasing the company's flexibility in its financing structure.
- Underwriter Selection: Guggenheim Securities and Cantor are acting as joint bookrunning managers for the offering, indicating Phathom's strategic partnerships in the capital markets, which can enhance its market credibility and financing efficiency.
- Planned Use of Funds: Phathom intends to utilize the net proceeds for general corporate purposes, including working capital and commercialization and R&D expenses, demonstrating the company's strategic positioning for future growth and its ability to capitalize on market opportunities.
See More
Phathom Pharmaceuticals Plans Public Offering to Fund R&D
- Public Offering Announcement: Phathom Pharmaceuticals has announced its intention to conduct a public offering of common stock or pre-funded warrants, aiming to raise funds for general corporate purposes, particularly for research and development and commercialization expenses.
- Underwriter's Option: The company plans to grant underwriters a 30-day option to purchase up to an additional 15% of the total securities offered, which will provide flexibility for potential fundraising and enhance market confidence.
- Market Uncertainty: Although the company has filed a registration statement, there is no definitive timeline or terms for the offering, indicating that market conditions may significantly impact the issuance and investor decisions.
- Strategic Focus: The proceeds from this offering will support Phathom's innovative drug development in gastrointestinal diseases, particularly the commercialization of its first-in-class drug vonoprazan, aiming to enhance the company's competitive position in the biopharmaceutical industry.
See More
GH Research (GHRS) Stock Surges 22.36% Ahead of Key Update
- Stock Surge: GH Research PLC's stock surged 22.36% to $16.20, gaining $2.96, primarily driven by investor anticipation for a key company update scheduled for January 5, 2026.
- Key Update Announcement: The company will disclose the status of its Investigational New Drug Application (IND) for GH001 and progress on its global pivotal Phase 3 program for treatment-resistant depression (TRD), which is expected to have significant implications for the treatment landscape.
- Investor Interest Spike: The strong investor interest surrounding the upcoming announcement has led to a substantial increase in GH Research's stock price, reflecting heightened market confidence in the biotech sector.
- Positive Market Reaction: Despite no new updates from other biotech firms like Phathom Pharmaceuticals and Forte Biosciences, their stock prices also rose, indicating a broader optimistic sentiment in the biotechnology industry.
See More
Phathom Pharmaceuticals Sees Q4 Sales of $57-58M, Prices $130M Public Offering
- Sales Forecast Increase: Phathom Pharmaceuticals anticipates Q4 2025 sales between $57 million and $58 million, exceeding the consensus estimate of $56.16 million, indicating strong market competitiveness and growing product demand.
- Annual Revenue Guidance Update: The company has raised its full-year 2025 revenue guidance to approximately $174.5 million to $175.5 million from the previous $170 million to $175 million, reflecting an optimistic outlook for future performance.
- Prescription Milestone: Voquezna has surpassed one million prescriptions dispensed in the U.S. since its launch, demonstrating strong market acceptance and clinical demand for the treatment of gastroesophageal reflux disease (GERD).
- Financing Plan: Phathom Pharmaceuticals successfully priced its underwritten public offering of 6.875 million shares at $16 per share, expected to raise approximately $130 million for general corporate purposes, including working capital and R&D expenses, showcasing the company's financial support capability for future growth.
See More
Northrop Grumman Shares Rise 6.84% Following Military Budget Proposal
- Stock Surge: Northrop Grumman's shares rose 6.84% following President Trump's proposal to increase the 2027 military budget from $1 trillion to $1.5 trillion, indicating market optimism about defense spending that could drive future performance growth.
- Market Reaction: Despite a generally poor market performance, Northrop Grumman's stock increased, reflecting investor confidence in the defense sector, particularly amid current geopolitical tensions where defense spending may become a key economic growth driver.
- Industry Trends: With the anticipated increase in defense budgets, Northrop Grumman is likely to secure more government contracts, enhancing its market share and profitability, thereby solidifying its leadership position in the defense industry.
- Investor Focus: The market remains highly attentive to upcoming economic data, especially initial jobless claims and trade deficit figures, which could influence overall market sentiment and investment decisions.
See More
AZZ Inc Reports Q3 Earnings Beat, Shares Rise 2.1%
- Earnings Beat: AZZ Inc reported adjusted earnings of $1.52 per share for Q3, surpassing market expectations of $1.47, indicating sustained profitability that may attract more investor interest.
- Sales Growth: The company achieved sales of $425.746 million, exceeding expectations of $418.164 million, demonstrating strong market demand and further solidifying its position in the industry.
- Stock Price Surge: In pre-market trading, AZZ Inc shares rose 2.1% to $112.09, reflecting a positive market reaction to its earnings report, which could boost investor confidence in subsequent trading days.
- Optimistic Market Outlook: With improved performance, AZZ Inc is poised to continue attracting investment and enhancing its competitive edge, particularly in the context of the current economic recovery.
See More
Phathom Pharmaceuticals Prices 6.875M Share Offering at $16, Raising $130M
- Public Offering Pricing: Phathom Pharmaceuticals has priced its offering of 6.875 million shares of common stock at $16 per share, along with 1.25 million pre-funded warrants, aiming to raise approximately $130 million to strengthen its capital base for future R&D and commercialization efforts.
- Pre-Funded Warrant Details: The pre-funded warrants are priced at $15.999 each, reflecting the common stock price minus a $0.001 exercise price, showcasing the company's flexibility in its financing structure.
- Underwriter Selection: Guggenheim Securities and Cantor are acting as joint bookrunning managers for the offering, indicating Phathom's strategic partnerships in the capital markets, which can enhance its market credibility and financing efficiency.
- Planned Use of Funds: Phathom intends to utilize the net proceeds for general corporate purposes, including working capital and commercialization and R&D expenses, demonstrating the company's strategic positioning for future growth and its ability to capitalize on market opportunities.
See More
Phathom Pharmaceuticals Plans Public Offering to Fund R&D
- Public Offering Announcement: Phathom Pharmaceuticals has announced its intention to conduct a public offering of common stock or pre-funded warrants, aiming to raise funds for general corporate purposes, particularly for research and development and commercialization expenses.
- Underwriter's Option: The company plans to grant underwriters a 30-day option to purchase up to an additional 15% of the total securities offered, which will provide flexibility for potential fundraising and enhance market confidence.
- Market Uncertainty: Although the company has filed a registration statement, there is no definitive timeline or terms for the offering, indicating that market conditions may significantly impact the issuance and investor decisions.
- Strategic Focus: The proceeds from this offering will support Phathom's innovative drug development in gastrointestinal diseases, particularly the commercialization of its first-in-class drug vonoprazan, aiming to enhance the company's competitive position in the biopharmaceutical industry.
See More
GH Research (GHRS) Stock Surges 22.36% Ahead of Key Update
- Stock Surge: GH Research PLC's stock surged 22.36% to $16.20, gaining $2.96, primarily driven by investor anticipation for a key company update scheduled for January 5, 2026.
- Key Update Announcement: The company will disclose the status of its Investigational New Drug Application (IND) for GH001 and progress on its global pivotal Phase 3 program for treatment-resistant depression (TRD), which is expected to have significant implications for the treatment landscape.
- Investor Interest Spike: The strong investor interest surrounding the upcoming announcement has led to a substantial increase in GH Research's stock price, reflecting heightened market confidence in the biotech sector.
- Positive Market Reaction: Despite no new updates from other biotech firms like Phathom Pharmaceuticals and Forte Biosciences, their stock prices also rose, indicating a broader optimistic sentiment in the biotechnology industry.
See More
